Jaguar Health (NASDAQ:JAGX) Announces Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Jaguar Health (NASDAQ:JAGXGet Rating) posted its earnings results on Tuesday. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.19), MarketWatch Earnings reports. Jaguar Health had a negative return on equity of 269.54% and a negative net margin of 1,023.99%. During the same quarter in the previous year, the firm earned ($0.30) earnings per share.

NASDAQ:JAGX traded up $0.04 during midday trading on Friday, hitting $0.42. The company had a trading volume of 11,480 shares, compared to its average volume of 1,080,933. The company has a market capitalization of $31.98 million, a PE ratio of -0.33 and a beta of 1.82. The company has a quick ratio of 1.52, a current ratio of 1.84 and a debt-to-equity ratio of 2.11. Jaguar Health has a 52-week low of $0.34 and a 52-week high of $6.84. The stock’s fifty day moving average price is $0.51 and its 200-day moving average price is $0.93.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JAGX. Citigroup Inc. bought a new stake in Jaguar Health during the first quarter worth about $34,000. Morgan Stanley purchased a new position in shares of Jaguar Health during the 1st quarter valued at about $159,000. Virtu Financial LLC lifted its position in Jaguar Health by 234.6% in the 4th quarter. Virtu Financial LLC now owns 130,197 shares of the biotechnology company’s stock worth $135,000 after buying an additional 91,280 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Jaguar Health in the fourth quarter worth approximately $95,000. Finally, Bank of New York Mellon Corp grew its position in Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 141,796 shares during the last quarter. Institutional investors and hedge funds own 11.91% of the company’s stock.

Several research firms recently issued reports on JAGX. Zacks Investment Research raised Jaguar Health from a “sell” rating to a “hold” rating in a research note on Thursday, January 20th. began coverage on Jaguar Health in a research report on Thursday. They set a “hold” rating for the company.

About Jaguar Health (Get Rating)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Read More

Earnings History for Jaguar Health (NASDAQ:JAGX)

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.